Levomac OZ Tablet is a combination antibiotic formulation containing Levofloxacin 250mg and Ornidazole 500mg, indicated for the treatment of various bacterial and protozoal infections. Levofloxacin, a fluoroquinolone antibiotic, exerts its bactericidal effect by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing DNA replication and transcription. Ornidazole, a nitroimidazole derivative, is effective against anaerobic bacteria and protozoa by disrupting DNA synthesis and causing cell death. This synergistic combination is particularly useful in managing mixed infections involving both aerobic and anaerobic organisms, such as intra-abdominal infections, pelvic inflammatory disease, bacterial vaginosis, and certain gastrointestinal infections. Levomac OZ Tablet is prescribed based on susceptibility patterns and clinical judgment, ensuring optimal therapeutic outcomes. It is essential to adhere to the prescribed dosage and duration to prevent the development of resistance. Common adverse effects may include gastrointestinal disturbances, headache, dizziness, and, rarely, hypersensitivity reactions. Caution is advised in patients with a history of hypersensitivity to fluoroquinolones or nitroimidazoles, as well as those with renal impairment. Levomac OZ Tablet should be used under medical supervision, with periodic monitoring as necessary to ensure safety and efficacy.